Direkt zum Inhalt
Merck
  • IL-1 receptor blockade alleviates endotoxin-mediated impairment of renal drug excretory functions in rats.

IL-1 receptor blockade alleviates endotoxin-mediated impairment of renal drug excretory functions in rats.

American journal of physiology. Renal physiology (2014-12-17)
Zuzana Kadova, Eva Dolezelova, Jolana Cermanova, Milos Hroch, Tomas Laho, Lucie Muchova, Frantisek Staud, Libor Vitek, Jaroslav Mokry, Jaroslav Chladek, Zuzana Havlinova, Milan Holecek, Stanislav Micuda
ZUSAMMENFASSUNG

The aim of our study was to investigate whether two potent anti-inflammatory agents, dexamethasone and anakinra, an IL-1 receptor antagonist, may influence acute kidney injury (AKI) and associated drug excretory functions during endotoxemia (LPS) in rats. Ten hours after LPS administration, untreated endotoxemic rats developed typical symptoms of AKI, with reduced GFR, impaired tubular excretion of urea and sodium, and decreased urinary excretion of azithromycin, an anionic substrate for multidrug resistance-transporting proteins. Administration of both immunosuppressants attenuated the inflammatory response, liver damage, AKI, and increased renal clearance of azithromycin mainly by restoration of GFR, without significant influence on its tubular secretion. The lack of such an effect was related to the differential effect of both agents on the renal expression of individual drug transporters. Only dexamethasone increased the urinary clearance of bile acids, in accordance with the reduction of the apical transporter (Asbt) for their tubular reabsorption. In summary, our data demonstrated the potency of both agents used for the prevention of AKI, imposed by endotoxins, and for the restoration of renal drug elimination, mainly by the improvement of GFR. The influence of both drugs on altered tubular functions and the expression of drug transporters was differential, emphasizing the necessity of knowledge of transporting pathways for individual drugs applied during sepsis. The effect of anakinra suggests a significant contribution of IL-1 signaling to the pathogenesis of LPS-induced AKI.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Dexamethason, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethason, ≥98% (HPLC), powder
Sigma-Aldrich
Dexamethason, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Azithromycin
USP
Dexamethason, United States Pharmacopeia (USP) Reference Standard
USP
Azithromycin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
3′-Azido-3′-Desoxythymidin, ≥98% (HPLC)
Sigma-Aldrich
Dexamethason, meets USP testing specifications
Supelco
Dexamethason, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Monoclonal Anti-P-Glycoprotein (MDR) antibody produced in mouse, clone F4, ascites fluid
USP
Zidovudin, United States Pharmacopeia (USP) Reference Standard
USP
Azithromycin-Identität, United States Pharmacopeia (USP) Reference Standard
Azithromycin, European Pharmacopoeia (EP) Reference Standard
Supelco
Zidovudin, Pharmaceutical Secondary Standard; Certified Reference Material
Azithromycin für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Dexamethason, tested according to Ph. Eur.
Sigma-Aldrich
Anti-Heme Oxygenase-1 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
Dexamethason, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexamethason, VETRANAL®, analytical standard
Azithromycin für die Preakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Dexamethason für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Anti-SLC22A7 (AB1) antibody produced in rabbit, affinity isolated antibody
Dexamethason, British Pharmacopoeia (BP) Assay Standard
Dexamethason für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Zidovudin, European Pharmacopoeia (EP) Reference Standard